acut
infecti
nonbacteri
gastroenter
a
children
common
caus
hospit
first
describ
zahorski
winter
vomit
diseas
long
assum
due
viral
etiolog
advent
newer
technolog
abl
identifi
specif
vruse
infect
patient
a
attribut
rotaviru
norwalklik
virus
virus
includ
corona
viruslik
particl
adenovirus
astrovirus
calicivirus
may
also
caus
a
diagnos
made
aid
electron
microscopi
em
immunoelectronmicroscopi
tissu
cultur
varieti
serolog
techniqu
includ
enzymelink
immunosorb
assay
elisa
radioimmunoassay
ria
demonstr
viru
stool
along
serolog
evid
antibodi
patient
gastroenter
strong
evid
caus
role
viru
know
norwalklik
virus
rotavirus
norwalk
viru
norwalklik
virus
ire
associ
gastroenter
usual
outsid
infant
age
group
diseas
explos
onset
short
durat
hour
usual
selflimit
characterist
occur
epidem
symptom
includ
yomit
diarrhea
nausea
abdomin
cramp
lowgrad
fever
anorexia
headach
malais
myalgia
mucos
lesion
proxim
small
bowel
produc
viru
antibodi
present
adult
usual
first
appear
late
adolesc
earli
adult
life
role
antibodi
immun
reinfect
clear
diagnosi
made
immunoelectronmicroscopi
radioimmunoassay
also
use
neither
techniqu
avail
routin
basi
clinic
set
make
diagnosi
difficult
rotaviru
a
diseas
infant
young
children
usual
occur
cooler
month
temper
climat
ill
prolong
norwalklik
viru
a
usual
one
week
potenti
seriou
rotaviru
a
result
signific
morbid
mortal
third
world
nation
account
signific
number
infant
hospit
unit
state
children
year
age
antibodi
antibodi
appear
serotyp
specif
least
two
serotyp
rotaviru
afflict
human
symptom
includ
diarrhea
usual
severeand
wateri
vomit
fever
may
accompani
diarrhea
sever
dehydr
may
ensu
result
hospit
diagnosi
rotaviru
a
em
stool
specimen
method
readili
avail
set
altern
includ
elisa
ria
therapi
a
regardless
viral
etiolog
fluid
electrolyt
replac
avail
antivir
therapi
infect
prevent
depend
interrupt
fecalor
rout
cycl
immun
rotaviru
still
experiment
state
may
avail
year
yet
candid
norwalkviru
vaccin
develop
acut
infecti
nonbacteri
gastroenter
result
high
morbid
mortal
develop
nation
unit
state
account
signific
number
infant
hospit
well
day
lost
school
work
physician
lay
person
becom
quit
exercis
acquir
immun
defici
syndrom
aid
see
idn
volum
number
page
descript
disord
anxieti
stem
part
unknown
caus
mode
transmiss
aid
virtual
everyon
believ
caus
infecti
agent
probabl
transmit
blood
andor
intim
contact
fromwith
infect
patient
belief
enhanc
report
instanc
children
receiv
blood
blood
product
includ
hemophilia
recipi
coagul
factor
prepar
donor
blood
one
persist
fear
emphas
larg
number
direct
inquiri
possibl
acquisit
f
aid
hepat
b
viru
vaccin
hbvv
hbvv
suspect
prepar
plasma
donat
hepat
b
surfac
antigen
hbsag
posit
person
hbsagposit
individu
frequent
group
also
suscept
aid
especi
male
homosexu
person
use
illicit
drug
intraven
rout
sinc
latter
group
may
donat
blood
individu
conclud
put
aid
agent
may
present
blood
donat
hbsag
prepar
vaccin
thu
far
said
supposit
theori
anxieti
concern
mani
if
includ
chain
reason
none
known
certain
present
time
look
evid
draw
set
infer
likelihood
aid
transmiss
product
hbvv
first
certain
aid
caus
infecti
agent
although
like
possibl
prove
aid
result
noninfecti
stimulu
immun
complex
infecti
agent
much
concern
would
evapor
aid
caus
agent
characterist
agent
environment
stabil
mode
transmiss
determin
possibl
degre
risk
acquisit
product
deriv
blood
second
thousand
person
receiv
hbvv
aid
experienc
group
group
compar
riskofaid
statu
receiv
hbvv
experi
reassur
publish
npubfish
data
suggest
risk
medic
staff
given
hbvv
origin
tial
none
develop
aid
last
three
year
similarli
case
aid
appear
specif
high
risk
vaccin
group
steven
report
male
homosexu
given
hbvv
one
develop
kaposi
sarcoma
compon
aid
four
year
later
anoth
recipi
second
trial
develop
pneumocysti
carinii
pneumonia
two
year
vaccin
receipt
steven
calcul
frequenc
vaccin
group
howev
men
screen
vaccin
trial
reject
alreadi
infect
hepat
b
number
case
aid
occur
incid
thu
rate
higher
nonrecipi
hbvv
ident
risk
categori
dual
find
case
low
risk
group
receiv
hbvv
excess
hbvv
recipi
high
risk
group
compar
nonhbvv
recipi
group
suggest
risk
vaccin
third
prepar
test
hbvv
among
rigor
vaccin
product
know
final
hbvv
prepar
individu
circul
infecti
hepat
b
viru
prone
infect
manufactur
establish
product
protocol
includ
three
differ
mode
kill
infecti
agent
step
known
inactiv
repres
virus
type
mani
type
isol
infecti
agent
done
manufactur
process
infecti
agent
isol
final
one
view
entir
mass
data
reason
conclus
demonstr
risk
acquir
aid
hbvv
center
diseas
control
recent
report
aid
among
individu
receiv
hbvv
sinc
gener
avail
juli
two
case
occur
male
homosexu
refer
particip
vaccin
trial
prior
licensur
treat
elsewher
conjunct
cours
began
cough
first
intermitt
increas
hoars
group
spll
sever
decreas
intak
singl
spell
caus
stop
breath
brought
admiss
resucit
success
two
sibl
age
year
report
good
health
sibl
similar
symptom
day
earlier
none
children
receiv
immun
dtp
one
dose
week
ago
initi
assess
includ
rapid
labor
respir
hypotonia
mild
interstiti
retract
scatter
inspiratori
rale
intermitt
paroxym
cough
associ
cyanosi
question
whoop
within
hour
develop
sever
anoxia
respiratori
distress
apneic
episod
cyanosi
mark
pallor
requir
assist
ventil
endotrach
tube
next
day
period
develop
gener
grand
mal
seizur
requir
initi
mainten
phenobarbit
cours
mark
need
central
hyperaliment
sever
anemia
intercurr
urinari
tract
infect
otiti
media
central
nervou
system
statu
uncertain
discharg
fluoresc
antibodi
test
posit
b
pertussi
organ
recov
nasopharyng
swab
ill
adenoviru
recov
nasopharyng
specimen
hospit
bill
profession
fee
total
written
much
pertussi
column
recent
month
rather
repeat
fact
figur
thought
display
case
detail
would
provid
person
version
statist
human
toll
famili
cost
obviou
ill
conceiv
prevent
sibl
dtp
immun
appropri
time
appear
acquir
pertussi
sister
import
concomit
adenoviru
controversi
expert
believ
agent
contribut
sever
express
pertussi
care
infant
similar
patient
without
posit
adenoviru
isol
furor
pro
con
pertussi
pertussi
vaccin
one
forget
diseas
still
occur
still
sever
even
lethal
report
patient
remind
fact
keep
debat
perspect
review
inpati
record
demonstr
least
infant
hospit
pertussi
last
three
year
indetermin
number
older
infant
children
treat
outpati
hospit
children
rang
month
month
age
cost
hospit
vari
littl
alfr
sabin
cowork
report
success
immun
children
without
matern
antibodi
use
aerosol
nasal
vaccin
older
children
without
residu
matern
antibodi
inhal
undilut
aerosol
nasal
vaccin
produc
antibodi
respons
human
diploid
cell
vaccin
use
stabil
human
albumin
compar
trial
chick
embryo
fibroblast
vaccin
contain
ten
time
viru
stabil
hyperton
sugar
solut
without
ad
protein
less
success
achiev
antibodi
respons
dr
sabin
group
believ
hyperton
sugar
solut
may
respons
lesser
efficaci
discuss
note
titer
children
transplacent
transfer
matern
antibodi
high
prevent
immun
respons
aerosol
vaccin
level
type
prevent
respons
subcutan
inject
current
employ
measl
vaccin
immedi
clinic
reaction
seen
children
inhal
aerosol
vaccin
although
subsequ
reaction
among
children
success
go
elsevi
scienc
publish
co
inc
